▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.
Due to the recent approval of the vaccine by the EMA and European Commission, the Summary of Product Characteristics for COMIRNATY available here, will be available soon on the French Public database of medications.